Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nutrition
Published in: European Journal of Nutrition 2/1998

01-06-1998 | Original contribution

Influence of the dosing frequency of parathyroid hormone-(1–38) on its anabolic effect in bone and on the balance of calcium, phosphorus and magnesium

Authors: J.-L. Riond, I. Goliat-von Fischer, B. Küffer, A. Toromanoff, R. Forrer

Published in: European Journal of Nutrition | Issue 2/1998

Login to get access
Metadata
Title
Influence of the dosing frequency of parathyroid hormone-(1–38) on its anabolic effect in bone and on the balance of calcium, phosphorus and magnesium
Authors
J.-L. Riond
I. Goliat-von Fischer
B. Küffer
A. Toromanoff
R. Forrer
Publication date
01-06-1998
Publisher
Steinkopff-Verlag
Published in
European Journal of Nutrition / Issue 2/1998
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s003940050015

Other articles of this Issue 2/1998

European Journal of Nutrition 2/1998 Go to the issue

Originalarbeit

Zufuhr an Vitaminen und Mineralstoffen aus Nahrungsergänzungspräparaten in der MONICA-Querschnittsstudie 1994/95 der Studienregion Augsburg

Editorial

Important information

Kurzmitteilung

Carotinoide und Vitamin A in Fischproben

Übersicht

Falvonole, Flavone und Anthocyane als natürliche Antioxidantien der Nahrung und ihre mögliche Rolle bei der Prävention chronischer Erkrankungen

Originalbeiträge

Phenolsäurezufuhr Erwachsener in einem bayerischen Teilkollektiv der Nationalen Verzehrsstudie

Originalarbeit

Methodenvergleich zur Charakterisierung thermisch veränderter Fritierfette und -öle
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits